TTrialPathMatch Me to Trials
← Back to trials
RecruitingCongestive Heart FailureHeart Failure, SystolicHeart Failure

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Eligible age

18–80 yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.

Sponsor: Sardocor Corp.

Where it's recruiting

California

San Diego · San Francisco

Missouri

St Louis

Texas

Dallas

Washington

Seattle

Source: ClinicalTrials.gov · NCT04703842 · last updated 2024-03-26